Neurocrine Biosciences, Inc. (NASDAQ:NBIX)‘s stock had its “outperform” rating restated by equities research analysts at Oppenheimer Holdings, Inc. in a research note issued on Wednesday. They currently have a $70.00 price target on the stock. Oppenheimer Holdings, Inc.’s target price points to a potential upside of 49.80% from the company’s current price.

A number of other analysts also recently weighed in on NBIX. Piper Jaffray Companies reiterated an “outperform” rating and issued a $80.00 price target on shares of Neurocrine Biosciences in a research report on Tuesday, March 7th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $80.00 price target on shares of Neurocrine Biosciences in a research report on Tuesday, March 7th. Needham & Company LLC reiterated a “buy” rating and issued a $62.00 price target on shares of Neurocrine Biosciences in a research report on Friday, March 17th. Barclays PLC reiterated an “overweight” rating and issued a $60.00 price target on shares of Neurocrine Biosciences in a research report on Monday, March 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $58.00 price target on shares of Neurocrine Biosciences in a research report on Tuesday, April 4th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and sixteen have issued a buy rating to the stock. Neurocrine Biosciences currently has an average rating of “Buy” and an average price target of $67.69.

Neurocrine Biosciences (NASDAQ:NBIX) traded down 0.23% during midday trading on Wednesday, hitting $46.73. 777,611 shares of the stock were exchanged. The firm’s market capitalization is $4.12 billion. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $55.38. The company has a 50 day moving average price of $47.45 and a 200 day moving average price of $45.18.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by $0.23. During the same quarter last year, the business posted ($0.22) EPS. Equities analysts anticipate that Neurocrine Biosciences will post ($2.46) EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences, Inc. (NBIX) Given “Outperform” Rating at Oppenheimer Holdings, Inc.” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/07/09/neurocrine-biosciences-inc-nbix-given-outperform-rating-at-oppenheimer-holdings-inc.html.

In other news, CEO Kevin Charles Gorman sold 19,596 shares of the firm’s stock in a transaction that occurred on Wednesday, April 12th. The shares were sold at an average price of $50.42, for a total transaction of $988,030.32. Following the completion of the transaction, the chief executive officer now directly owns 332,913 shares of the company’s stock, valued at approximately $16,785,473.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Corinne H. Nevinny sold 5,000 shares of the firm’s stock in a transaction that occurred on Friday, May 5th. The stock was sold at an average price of $53.98, for a total transaction of $269,900.00. Following the transaction, the director now directly owns 34,603 shares of the company’s stock, valued at $1,867,869.94. The disclosure for this sale can be found here. Insiders have sold a total of 104,360 shares of company stock valued at $5,501,889 over the last ninety days. Company insiders own 4.80% of the company’s stock.

Several institutional investors have recently modified their holdings of NBIX. BlackRock Inc. boosted its position in shares of Neurocrine Biosciences by 14,216.0% in the first quarter. BlackRock Inc. now owns 5,031,933 shares of the company’s stock valued at $217,884,000 after buying an additional 4,996,784 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Neurocrine Biosciences by 554.4% in the first quarter. Wellington Management Group LLP now owns 2,407,376 shares of the company’s stock valued at $104,240,000 after buying an additional 2,039,509 shares in the last quarter. Janus Capital Management LLC boosted its position in Neurocrine Biosciences by 85.0% in the first quarter. Janus Capital Management LLC now owns 4,359,384 shares of the company’s stock valued at $188,759,000 after buying an additional 2,002,899 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Neurocrine Biosciences by 126.0% in the first quarter. Goldman Sachs Group Inc. now owns 1,743,949 shares of the company’s stock valued at $75,513,000 after buying an additional 972,434 shares in the last quarter. Finally, Norges Bank purchased a new position in Neurocrine Biosciences during the fourth quarter valued at $34,777,000. 95.90% of the stock is owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.